natgillin/translations-raw huggingface dataset:
The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782). 
Študija ACTIVE-A (n = 7.554) je bila multicentrična, randomizirana, dvojno slepa, s placebom kontrolirana študija, ki je primerjala klopidogrel 75 mg/dan + ASA (n = 3.772) in placebo + ASA (n = 3.782).
Pharmacotherapeutic group: Antithrombotic agents, platelet aggregation inhibitors excl. heparin, ATC code: B01AC-04. 
Farmakoterapevtska skupina: antitrombotiki, zaviralci agregacije trombocitov brez heparina, oznaka ATC: B01AC04.
Based on enrollment criteria, physicians enrolled patients in ACTIVE-W if they were candidates for vitamin K antagonist (VKA) therapy (such as warfarin). 
Na podlagi meril za vključitev so zdravniki bolnike vključili v ACTIVE-W, če so bili kandidati za zdravljenje z antagonistom vitamina K (VKA), npr. z varfarinom.
Overall, 645 of 646 patients with STEMI or NSTEMI or unstable angina were analyzed (de-escalated DAPT (n=322); unchanged DAPT (n=323)). 
V celoti so analizirali 645 od 646 bolnikov s STEMI, NSTEMI ali nestabilno angino pektoris (deeskalirano DAPT (n = 322), nespremenjeno DAPT (n = 323)).
• Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 
- odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
The ACTIVE-W study demonstrated that anticoagulant treatment with vitamin K antagonists was more effective than with clopidogrel and ASA. 
Študija ACTIVE-W je pokazala, da je bilo zdravljenje z antagonisti vitamina K učinkovitejše kot zdravljenje s klopidogrelom in ASA.
TOPIC (Timing Of Platelet Inhibition after acute Coronary syndrome) This randomized, open-label trial included ACS patients requiring PCI. 
Študija TOPIC (Tempiranje zavrtja trombocitov po akutnem koronarnem sindromu) To randomizirano, odprto preskušanje je vključilo bolnike z AKS, ki so potrebovali PKI.
If HPR≥46 units, the patients were escalated back to prasugrel 5 or 10 mg/d for 11.5 months; if HPR<46 units, the patients continued on clopidogrel 75 mg/d for 11.5 months. 
Če je bil rezultat HPR ≥ 46 enot, je bila izvedena ponovna eskalacija na prasugrel 5 mg ali 10 mg/dan za 11,5 meseca; če je bil rezultat HPR < 46 enot, so bolniki nadaljevali zdravljenje s klopidogrelom 75 mg/dan v obdobju 11,5 meseca.
• If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain. 
- če imate zdravstveno stanje, ki trenutno povzroča krvavitev, npr. rana na želodcu ali možganska krvavitev.
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below. 
Klinično pomembni neželeni učinki, zabeleženi v študijah CAPRIE, CURE, CLARITY in COMMIT, so predstavljeni spodaj.
• If you suffer from severe liver disease. 
- če imate hudo jetrno obolenje.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including medicines obtained without a prescription. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7-10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover. 
Zaradi ireverzibilne vezave se učinek na izpostavljene trombocite ohrani vso njihovo preostalo življenjsko dobo (približno 7-10 dni), normalno delovanje trombocitov pa se obnovi s hitrostjo, ki je v skladu s premeno trombocitov.
• Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1). 
Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje 5.1.
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidogrel Krka d.d. 
Priporočeni odmerek, vključno za bolnike, ki imajo bolezensko stanje, imenovano "atrijska fibrilacija" (nepravilen srčni utrip), je ena 75 mg tableta zdravila Clopidogrel Krka d.d.
In addition to clinical studies experience, adverse reactions have been spontaneously reported. 
Poleg neželenih učinkov v kliničnih študijah so bili neželeni učinki prijavljeni tudi spontano.
For patients over 75 years of age clopidogrel should be initiated without a loading dose. 
Pri starejših od 75 let začnemo zdravljenje s klopidogrelom brez udarnega odmerka.
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography. 
Primarni opazovani dogodek je bila sočasna navzočnost zamašene arterije, ki je povzročila MI na angiogramu pred odpustom ali smrt ali ponovni miokardni infarkt pred koronarno angiografijo.
The major exclusion criteria for patients were documented peptic ulcer disease within the previous 6 months; prior intracerebral hemorrhage; significant thrombocytopenia (platelet count < 50 x 10 
Glavna merila za nevključitev bolnikov so bila potrjena peptična ulkusna bolezen v preteklih 6 mesecih, predhodna intracerebralna krvavitev, pomembna trombocitopenija (število trombocitov < 50 x 10
- You have an irregular heartbeat, a condition called ‘atrial fibrillation', and you cannot take medicines known as ‘oral anticoagulants' (vitamin K antagonists) which prevent new clots from forming and prevent existing clots from growing. 
- imate neredno bitje srca, motnjo, imenovano "atrijska fibrilacija", in ne morete prejemati zdravil, imenovanih "peroralni antikoagulanti" (antagonisti vitamina K), ki preprečujejo nastajanje novih krvnih strdkov in preprečujejo rast obstoječih krvnih strdkov.
Bleeding and haematological disorders 
Krvavitve in hematološke motnje
In contrast, post-hoc analyses demonstrated statistically significant increases in the bleeding risk with the more potent P2Y12 inhibitors, occurring predominantly during the maintenance phase, after the first month post-ACS. 
Nasprotno pa so post hoc analize pokazale, da je z močnejšimi zaviralci P2Y12 statistično značilno večje tveganje za krvavitve; krvavitve se pojavijo pretežno med fazo vzdrževalnega zdravljenja, po prvem mesecu po AKS.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel plus ASA, and 6.3% for placebo plus ASA. 
Pri bolnikih, ki so ostali na zdravljenju do 5 dni pred koronarno premostitveno operacijo, je bil delež dogodkov 9,6 % za klopidogrel in ASA in 6,3 % za placebo in ASA.
A total of 23.0% of patients received anti-arrhythmics, 52.1% beta-blockers, 54.6% ACE inhibitors, and 25.4% statins. 
V celoti je 23,0 % bolnikov prejemalo antiaritmike, 52,1 % blokatorje beta, 54,6 % zaviralce ACE in 25,4 % statine.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel-treated group and 363 (5.8%) in the placebo-treated group]. 
Ta korist je v glavnem nastala kot posledica statistično pomembnega zmanjšanja incidence MI (287 /4,6 %/ v skupini, zdravljeni s klopidogrelom, in 363 /5,8 %/ v placebo skupini).
Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race. 
V celoti je bil klopidogrel v odmerku 75 mg/dan v študiji CAPRIE, primerljiv z ASA v odmerku 325 mg/dan, ne glede na starost, spol ali raso.
Manufacturer: 
Proizvajalec
In view of the lack of data, clopidogrel cannot be recommended during the first 7 days after acute ischaemic stroke. 
Nedavna ishemična kap Zaradi pomanjkanja podatkov se klopidogrel ne priporoča prvih sedem dni po akutni ishemični kapi.
Thienopyridines may cause mild to severe allergic reactions such as rash, angioedema, or haematological cross-reactions such as thrombocytopaenia and neutropaenia. 
Tienopiridini lahko povzročijo blage do hude alergijske reakcije, na primer izpuščaj, angioedem ali hematološke navzkrižne reakcije, na primer trombocitopenijo in nevtropenijo.
• Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 
- Preobčutljivost na učinkovino ali katero koli pomožno snov, navedeno v poglavju 2 ali v poglavju 6.1.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Krka d.d.. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Clopidogrel Krka d.d..
Thus, beyond 3 months of treatment, the benefit observed in the clopidogrel + ASA group was not further increased, whereas the risk of haemorrhage persisted (see section 4.4). 
Tako se po več kot 3-mesečnem zdravljenju opažena korist v skupini, ki je jemala klopidogrel in ASA, ni povečevala, tveganje za krvavitev pa je ostalo (glejte poglavje 4.4).
contains clopidogrel and belongs to a group of medicines called antiplatelet medicinal products. 
vsebuje klopidogrel in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD). 
Nedavni miokardni infarkt (MI), nedavna kap ali ugotovljena periferna arterijska bolezen (PAD) Študija CAPRIE je vključevala 19.185 bolnikov z aterotrombozo, ki se je odrazila z nedavnim miokardnim infarktom (<35 dni), ishemično kapjo (med 7 dni in 6 meseci) ali razvito periferno arterijsko boleznijo (PAD).
Ask your pharmacist how to throw away you no longer use. 
O načinu odstranjevanja zdravila, ki ga ne uporabljate več, se posvetujte s farmacevtom.
film-coated tablet 
filmsko obložena tableta
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Nemčija
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers or antacids interfere with antiplatelet activity of clopidogrel. 
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. antagonisti histaminskih receptorjev H2 ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
Some other medicines may influence the use of Clopidogrel Krka d.d. 
Nekatera druga zdravila lahko vplivajo na jemanje zdravila Clopidogrel Krka d.d.
This benefit was consistent across all prespecified subgroups including patients' age and gender, infarct location, and type of fibrinolytic or heparin used. 
Ta koristni učinek se je pojavljal v vseh prehodno opredeljenih podskupinah glede na bolnikovo starost ali spol, mesto infarkta in vrsto uporabljenega fibrinolitika ali heparina.
You should also be given acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever as well as to prevent blood clotting) by your doctor. 
Zdravnik vam bo moral predpisati tudi acetilsalicilno kislino (učinkovina, ki je v številnih zdravilih proti bolečinam in za zniževanje zvišane telesne temperature, kot tudi za preprečevanje strjevanja krvi).
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively. 
Nove srčno-žilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem RT za 22 % (IZ: 8,6, 33,4), 32 % (IZ: 12,8, 46,4), 4 % (IZ: -26,9, 26,7), 6 % (IZ: -33,5, 34,3) in 14 % (IZ: -31,6, 44,2) med intervali, ki so trajali 0-1, 1-3, 3-6, 6-9 oziroma 9-12 mesecev.
CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy volunteers. 
Zdravila, ki so substrati CYP2C8: Klopidogrel pri zdravih prostovoljcih poveča izpostavljenost repaglinidu.
Blister of OPA/Alu/PVC-Alu containing 7, 14, 28, 30, 50, 56, 84, 90 and 100 film-coated tablets in the box. 
Na voljo so v pretisnih omotih (OPA/Al/PVC-Al) po 7, 14, 28, 30, 50, 56, 84, 90 in 100 filmsko obloženih tablet v škatli.
• For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose. 
- če je zamuda več kot 12 ur: bolnik naj naslednji odmerek vzame ob pravem času; odmerka ne sme podvojiti.
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage. 
- Aktivna patološka krvavitev, npr. peptična razjeda ali intrakranialna krvavitev.
TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes) 
TROPICAL-ACS (Preverjanje odzivnosti na zavrtje trombocitov ob kroničnem antiagregacijskem zdravljenju akutnih koronarnih sindromov)
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Krka d.d.. 
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden vzamete zdravilo Clopidogrel Krka d.d..
The cumulative incidence of all bleeding events (BARC class 1 to 5) was 9% (114 events) in the guided de-escalation group versus 11% (137 events) in the control group (p=0.14). 
Kumulativna pojavnost vseh krvavitev (razredi od 1 do 5 po BARC) je bila 9 % (114 dogodkov) v skupini z vodeno deeskalacijo in 11 % (137 dogodkov) v kontrolni skupini (p = 0,14).
The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel. 
Farmakokinetika digoksina ali teofilina nista bili spremenjeni ob sočasni uporabi klopidogrela.
A total of 99.7% of patients received fibrinolytics (fibrin specific: 68.7%, non- fibrin specific: 31.1%), 89.5% heparin, 78.7% beta blockers, 54.7% ACE inhibitors and 63% statins. 
Skupno 99,7 % bolnikov je dobivalo fibrinolitike (fibrinsko specifične: 68,7 %, nefebrinsko specifične: 31,1 %), 89,5 % heparin, 78,7 % zaviralce adrenergičnih receptorjev beta, 54,7 % zaviralce ACE in 63 % statine.
75 mg film-coated tablets 
75 mg filmsko obložene tablete
Switching from a more potent P2Y12 receptor inhibitor to clopidogrel in association with aspirin after acute phase in ACS has been evaluated in two randomized investigator-sponsored studies (ISS)TOPIC and TROPICAL-ACS - with clinical outcome data. 
Prehod z močnejšega zaviralca receptorjev P2Y12 na klopidogrel v kombinaciji z acetilsalicilno kislino po akutni fazi AKS so ocenili v dveh randomiziranih, s strani raziskovalcev sponzoriranih študij (ISS - investigator-sponsored studies) - TROPIC in TROPICAL-ACS - s podatki o kliničnih izidih.
In vitro studies have shown the increase in repaglinide exposure is due to inhibition of CYP2C8 by the glucuronide metabolite of clopidogrel. 
Študije in vitro so pokazale, da se izpostavljenost repaglinidu poveča zaradi zavrtja CYP2C8, ki ga povzroči glukuronidni presnovek klopidogrela.
- The other ingredients are microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000 and hydrogenated castor oil in the tablet core and polyvinyl alcohol, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172), talc and macrogol 3000 in the film-coating. 
- Druge sestavine zdravila so mikrokristalna celuloza, brezvodni koloidni silicijev dioksid, krospovidon (vrsta A), makrogol 6000 in hidrogenirano ricinusovo olje v jedru tablete ter polivinilalkohol, titanov dioksid (E171), rdeči železov oksid (E172), rumeni železov oksid (E172), smukec ter makrogol 3000 v filmski oblogi.
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with Vitamin K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. 
Preprečevanje aterotrombotičnih in trombemboličnih dogodkov pri atrijski fibrilaciji Pri odraslih bolnikih z atrijsko fibrilacijo, ki imajo vsaj en dejavnik tveganja za žilne dogodke in ki niso primerni za zdravljenje z antagonisti vitamina K (VKA) ter imajo majhno tveganje za krvavitev, je klopidogrel v kombinaciji z ASA indiciran za preprečevanje aterotrombotičnih in trombemboličnih dogodkov, vključno z možgansko kapjo.
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz. 
Med zdravila, ki so močni ali zmerni zaviralci CYP2C19, spadajo, na primer; omeprazol in esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, karbamazepin, efavirenz.
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics). 
Prevalenca alelov CYP 2C19, ki povzročijo srednjo ali slabo presnovo s CYP 2C19, se razlikuje glede na rasno/etnično pripadnost (glejte Farmakogenetika).
The clinical benefit provided by the more potent P2Y12 inhibitors, ticagrelor and prasugrel, in their pivotal studies is related to a significant reduction in recurrent ischaemic events (including acute and subacute stent thrombosis (ST), myocardial infarction (MI), and urgent revascularization). 
Klinična korist močnejših zaviralcev P2Y12, tikagrelorja in prasugrela, v njunih ključnih študijah je bila povezana z značilnim zmanjšanjem ponovnih ishemičnih dogodkov (vključno z akutno in subakutno trombozo žilne opornice (ST - stent thrombosis), miokardnim infarktom (MI) in nujno revaskularizacijo).
The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. 
Aktivni presnovek klopidogrela selektivno zavira vezavo adenozin-difosfata (ADP) na njegov trombocitni receptor P2Y12 in nadaljnjo aktivacijo glikoproteinskega kompleksa GP IIb/IIIa z ADP ter s tem zavre agregacijo trombocitov.
Serum sickness, anaphylactoid reactions cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Bolezni imunskega sistema serumska bolezen, anafilaktoidne reakcije, navzkrižna preobčutljivost med tienopiridini (kot sta tiklopidin in prasugrel) (glejte poglavje 4.4)*, avtoimuni inzulinski sindrom, ki lahko vodi v resno hipoglikemijo, še posebej pri bolnikih s HLA DRA4 podtipom (pogostejši v japonski populaciji)*
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel Krka d.d. 
Če ste doživeli hudo obliko bolečine v prsih (nestabilna angina ali srčni napad), so vam morda predpisali zdravilo Clopidogrel Krka d.d.
If you experience prolonged bleeding when taking Clopidogrel Krka d.d. 
Če doživite podaljšanje krvavitve v času jemanja zdravila Clopidogrel Krka d.d.
Bleeding events defined as all BARC occurred in 30 patients (9.3%) in the de-escalated DAPT group and in 76 patients (23.5%) in the unchanged DAPT group (p<0.01). 
Krvavitve, opredeljene kot vsi BARC, so se pojavile pri 30 bolnikih (9,3 %) v skupini z deeskaliranim DAPT in pri 76 bolnikih (23,5 %) v skupini z nespremenjenim DAPT (p < 0,01).
In patients with acute ST-segment elevation MI, safety and efficacy of clopidogrel have been evaluated in 2 randomised, placebo-controlled, double-blind studies, CLARITY and COMMIT. 
Pri bolnikih z akutnim miokardnim infarktom z elevacijo ST-spojnice sta bili varnost in učinkovitost klopidogrela vrednoteni v dveh randomiziranih s placebom kontroliranih dvojno slepih študijah CLARITY in COMMIT.
In ACTIVE-A, the rate of major bleeding was greater in the clopidogrel + ASA group than in the placebo + ASA group (6.7% versus 4.3%). 
V ACTIVE-A je bil delež hujših krvavitev v skupini s klopidogrelom + ASA večji kot v skupini s placebom + ASA (6,7 % v primerjavi s 4,3 %).
Ask your doctor or pharmacist for advice before taking any medicine. 
Posvetujete se z zdravnikom ali farmacevtom, preden vzamete katero koli zdravilo
This statistically significant difference was mainly driven by fewer bleeding events, with no difference reported in ischaemic endpoints (p=0.36), while BARC ≥2 bleeding occurred less frequently in the de-escalated DAPT group (4.0%) versus 14.9% in the unchanged DAPT group (p<0.01). 
Ta statistično značilna razlika je bil predvsem posledica manjšega števila krvavitev, medtem ko razlik v ishemičnih opazovanih dogodkih ni bilo (p = 0,36); krvavitve BARC ≥ 2 so bile manj pogoste v skupini z deeskaliranim DAPT (4,0 %) kot v skupini z nespremenjenim DAPT (14,9 %) (p < 0,01).
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow. 
Pri zdravljenju tega stanja vam je zdravnik v zamašeno ali zoženo arterijo morda moral vstaviti žilno opornico (stent), da je žilo razširil in obnovil krvni pretok.
The dose of 0.2 mg/kg achieved the mean percent inhibition of 49.3% (5 µM ADP-induced platelet aggregation) which was comparable to that of adults taking clopidogrel 75 mg/day. 
Odmerek 0,2 mg/kg je dosegel povprečno 49,3 % zavrtje (agregacija trombocitov povzročena s 5 µM ADP), primerljivo kot pri odraslih ob uporabi klopidogrela v odmerku 75 mg/dan.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the co-administration of phenobarbital or oestrogen. 
Poleg tega na farmakodinamično aktivnost klopidogrela ni pomembno vplivala sočasna uporaba fenobarbitala ali estrogena.
Clopidogrel significantly reduced the relative risk of death from any cause by 7% (p=0.029), and the relative risk of the combination of re-infarction, stroke or death by 9% (p=0.002), representing an absolute reduction of 0.5% and 0.9%, respectively. 
Klopidogrel je pomembno zmanjšal RT za smrt zaradi kateregakoli vzroka za 7 % (p = 0,029) in RT za ponovni infarkt, kap ali smrt za 9 % (p = 0,002), kar je predstavljalo absolutno zmanjšanje za 0,5 % oziroma 0,9 %.
In patients with atrial fibrillation, clopidogrel should be given as a single daily dose of 75 mg. ASA (75-100 mg daily) should be initiated and continued in combination with clopidogrel (see section 
Bolniki z atrijsko fibrilacijo morajo klopidogrel dobivati v enem dnevnem odmerku 75 mg. ASA (75-100 mg na dan) je treba uvesti in nadaljevati v kombinaciji s klopidogrelom (glejte poglavje 5.1).
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE 
A. PROIZVAJALEC (PROIZVAJALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ